Prothena Corporation plc (0PT.F)
- Previous Close
19.00 - Open
19.10 - Bid --
- Ask 19.60 x 10000
- Day's Range
19.10 - 19.30 - 52 Week Range
18.70 - 71.00 - Volume
30 - Avg. Volume
5 - Market Cap (intraday)
1.045B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-2.57 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
75.75
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
www.prothena.comRecent News: 0PT.F
Performance Overview: 0PT.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0PT.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0PT.F
Valuation Measures
Market Cap
1.05B
Enterprise Value
479.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.06
Price/Book (mrq)
1.98
Enterprise Value/Revenue
5.25
Enterprise Value/EBITDA
-2.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-160.91%
Return on Assets (ttm)
-16.42%
Return on Equity (ttm)
-24.85%
Revenue (ttm)
91.37M
Net Income Avi to Common (ttm)
-147.03M
Diluted EPS (ttm)
-2.57
Balance Sheet and Cash Flow
Total Cash (mrq)
618.83M
Total Debt/Equity (mrq)
2.11%
Levered Free Cash Flow (ttm)
-80.02M
Research Analysis: 0PT.F
Company Insights: 0PT.F
0PT.F does not have Company Insights